AliveCor
The company hopes that its more descriptive reports will distinguish the personal ECG offering from others limited to atrial fibrillation detection alone.
The tech company has made headlines over the past few days for its consumer health efforts related to its smartwatches.
The new algorithms will be able to detect for sinus rhythm with premature ventricular contractions, supraventricular ectopy and sinus rhythm with wide QRS.
Also: Upfront Healthcare announces $11.5M in funding; Solv scores $27M and adds to its team; Levels gets $12M in a seed round.
Also Proximie adds new CTO and chief commercial officer, and Cleo adds Karin Ajmani to its board.
The industry is embracing consumer-friendly offerings, says Dr. Jacqueline Shreibati, former chief medical officer of AliveCor, who describes how the company's personal ECG tech works.
From mobile ECGs to tele-rehabilitation to defibrillator delivery drones, a range of new data was on display at the American Heart Association Scientific Sessions 2019.
The news comes just a few months after AliveCor ended the sales of its FDA-cleared ECG wearable KardiaBand.
A new SEC document reveals the company has filed for a total offering of $9.1 million.